- Home
- EWTX vs OBK Comparison
EWTX vs OBK Comparison
Compare EWTX & OBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EWTX
- OBK
- Stock Information
- Founded
- EWTX 2017
- OBK 1912
- Country
- EWTX United States
- OBK United States
- Employees
- EWTX N/A
- OBK N/A
- Industry
- EWTX Biotechnology: Pharmaceutical Preparations
- OBK Major Banks
- Sector
- EWTX Health Care
- OBK Finance
- Exchange
- EWTX Nasdaq
- OBK Nasdaq
- Market Cap
- EWTX 1.5B
- OBK 1.1B
- IPO Year
- EWTX 2021
- OBK 2018
- Fundamental
- Price
- EWTX $13.03
- OBK $37.95
- Analyst Decision
- EWTX Buy
- OBK Buy
- Analyst Count
- EWTX 9
- OBK 5
- Target Price
- EWTX $39.89
- OBK $42.20
- AVG Volume (30 Days)
- EWTX 892.5K
- OBK 160.0K
- Earning Date
- EWTX 08-07-2025
- OBK 07-23-2025
- Dividend Yield
- EWTX N/A
- OBK 1.60%
- EPS Growth
- EWTX N/A
- OBK N/A
- EPS
- EWTX N/A
- OBK 2.43
- Revenue
- EWTX N/A
- OBK $351,348,000.00
- Revenue This Year
- EWTX N/A
- OBK $13.16
- Revenue Next Year
- EWTX N/A
- OBK $6.03
- P/E Ratio
- EWTX N/A
- OBK $15.61
- Revenue Growth
- EWTX N/A
- OBK 2.92
- 52 Week Low
- EWTX $10.60
- OBK $28.80
- 52 Week High
- EWTX $38.12
- OBK $41.17
- Technical
- Relative Strength Index (RSI)
- EWTX 35.20
- OBK 72.59
- Support Level
- EWTX $12.72
- OBK $35.56
- Resistance Level
- EWTX $13.37
- OBK $36.38
- Average True Range (ATR)
- EWTX 0.65
- OBK 0.80
- MACD
- EWTX -0.16
- OBK 0.26
- Stochastic Oscillator
- EWTX 24.22
- OBK 97.41
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.
About OBK Origin Bancorp Inc.
Origin Bancorp Inc is a financial holding company. The bank provides a broad range of financial services to businesses, municipalities, high-net-worth individuals, and retail clients. The bank principally operates in one business segment, community banking. The bank is engaged in attracting deposits from individuals and businesses and using these deposits and borrowed funds to originate commercial, residential mortgage, construction, and consumer loans. The bank generates the majority of its revenue from interest earned on loans and investments, service charges, and fees on deposit accounts.